Publications
Detailed Information
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Jaemoon | - |
dc.contributor.author | Go, Heounjeong | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Moon-Young | - |
dc.contributor.author | Nam, Soo Jeong | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Min, Hye Sook | - |
dc.contributor.author | Kim, Young Tae | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.date.accessioned | 2020-04-27T11:22:30Z | - |
dc.date.available | 2020-04-27T11:22:30Z | - |
dc.date.created | 2018-09-13 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.citation | Modern Pathology, Vol.28 No.9, pp.1154-1166 | - |
dc.identifier.issn | 0893-3952 | - |
dc.identifier.other | 53545 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165388 | - |
dc.description.abstract | Immunotherapies targeting the programmed cell death-1/programmed cell death-ligand 1 pathway have emerged as promising therapeutic strategies for lung cancer. However, the expression pattern and prognostic implications of programmed cell death-ligand 1 and 2 and programmed cell death-1 in comparison with the histology and genetic alterations in pulmonary adenocarcinomas remains unclear and thus were addressed here. Programmed cell death-ligand 1 and 2 expression in tumor cells and the quantities of programmed cell death-1(+) and CD8(+) tumor-infiltrating lymphocytes were immunohistochemically evaluated in 497 resected pulmonary adenocarcinomas and analyzed according to clinicopathological and genetic statuses. Programmed cell death-ligand 1 and 2 expression were observed in 59% and 64% of pulmonary adenocarcinomas, respectively, and showed a strong positive correlation with each other (P<0.001). Programmed cell death-ligand 1 expression was higher in nodal metastasis cases (P=0.006), smokers (P=0.056), poorly differentiated tumors and histologic subtypes of solid and micropapillary patterns (P<0.001). There was no significant difference in programmed cell death-ligand 1 and 2 expression according to EGFR mutation status. However, programmed cell death-ligand 1 expression was correlated with ALK translocation (P=0.054) and expression of EGFR and MET (P<0.001). Meanwhile, programmed cell death-ligand 2 expression was correlated with ALK translocation (P=0.052), and expression of MET (P<0.001) and ERBB2 (P=0.013). The numbers of CD8+ and programmed cell death-1+ lymphocytes were higher in smokers (P=0.012 and 0.016) and MET-expressing adenocarcinomas (P<0.001). Patients expressing programmed cell death-ligand 1 and/or high ratios of programmed cell death-1(+)/CD8(+) lymphocytes showed shorter disease-free survival (P=0.001). Our study demonstrated that programmed cell death-ligand 1 and 2 expression varied with histology, EGFR, ALK, MET, and ERBB2 statuses, and activation of the programmed cell death-1/programmed cell death-ligand 1 pathway may be a poor prognostic factor in pulmonary adenocarcinomas. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김영태 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 정두현 | - |
dc.identifier.doi | 10.1038/modpathol.2015.63 | - |
dc.citation.journaltitle | Modern Pathology | - |
dc.identifier.wosid | 000360664200001 | - |
dc.identifier.scopusid | 2-s2.0-84940722192 | - |
dc.citation.endpage | 1166 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 1154 | - |
dc.citation.volume | 28 | - |
dc.identifier.sci | 000360664200001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | CD8(+) T-LYMPHOCYTES | - |
dc.subject.keywordPlus | GENE COPY NUMBER | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | PROTEIN EXPRESSION | - |
dc.subject.keywordPlus | PD-L1 EXPRESSION | - |
dc.subject.keywordPlus | B7-H1 EXPRESSION | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | IMMUNE-SYSTEM | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.